CAR-T 细胞疗法是一种富有前景的实体瘤治疗方法。但要确定专门针对肿瘤抗原的适当 T 细胞受体（TCR）结构域依然是一个挑战。Toxicity, tumor activation, and tumor persistence are significant challenges to using CAR-T cell therapies for solid tumors.In this webinar, Twist Bioscience’s CSO, Aaron Sato, will present several proof-of-concept studies showing how these technologies can be utilized for cell therapies. Aaron will also be joined by Justin Farlow, CTO of Serotiny, who will tell the story of how Twist’s Combinatorial Assembly Libraries helped his company design and evaluate thousands of CARs, each with novel intracellular signaling architectures. 通过使用这些文库，Serotiny 快速地选择了多种新颖的 CAR 设计，进而增强原代 T 细胞的治疗性能。

Twist synthetic DNA technologies have enabled the development of precision antibody libraries designed to bind to G protein-coupled receptors (GPCRs). We have employed high throughput binding and functional assays to discover antibodies with agonist and antagonist profiles. This parallel functional screening was successfully employed for discovery of novel therapeutic antibody ligands for three GPCRs (called GLP1R, APJR and C5AR1). Twist synthetic DNA technologies allow for the design of novel antibody-based GPCR ligands with profiles for clinical therapeutic development.    

Bioscience 提供完整的按需基因到抗体高通量生产服务，以帮助集中和简化用于下游表征的抗体生产。我们的平台非常适合您在产能受限或增加抗体生产支持时段的探索过程。除了生产之外，我们还提供一系列表征服务，这些服务有助于缓解通常会给实验室带来负担的初始下游表征瓶颈。